Document Detail

Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation.
MedLine Citation:
PMID:  18797894     Owner:  NLM     Status:  MEDLINE    
At least 71 patients have been reported in which their otherwise typical subacute cutaneous lupus erythematosus (SCLE) skin lesions were felt to have been temporally associated with the systemic administration of a drug. The mean age of this cohort of drug-induced SCLE (DI-SCLE) patients was 59 years of age which is somewhat older than the mean age of previously reported idiopathic SCLE patient cohorts. Patients had been taking the suspected triggering drug for weeks to years before the onset of SCLE skin lesions. In addition, it was not unusual for 2-3 months to be required for resolution of the SCLE skin lesions following discontinuation of the triggering drug. A relatively large number of drugs representing different pharmacological classes have been implicated in the induction of SCLE. The drug classes that were more frequently encountered were those used for the treatment of cardiovascular disease, especially hypertension. Calcium channel blockers were especially common in this regard. Elderly individuals being treated for hypertension are often taking multiple classes of drugs that have been implicated in triggering SCLE (thiazide diuretics, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, beta-blockers). An approach to the management of DI-SCLE is presented. Ro/SS-A autoantibodies tended to remain present in the blood after resolution of drug-induced SCLE skin lesions. A common link between the disparate group of drug structures implicated in triggering SCLE is their tendencies to produce photosensitivity and lichenoid drug reactions. This leads to the speculation that DI-SCLE could represent a photo-induced isomorphic/Köebner response in an immunogenetically predisposed host.
Richard D Sontheimer; Clifford L Henderson; Renee H Grau
Related Documents :
22557604 - Pharmacognostical studies on the root of sahachara nilgirianthus heyneanus (nees) breme...
22546604 - Progressing preclinical drug candidates: strategies on preclinical safety studies and t...
6861634 - Nifedipine: two new uses.
22777274 - An overview on mixed action drugs for the treatment of overactive bladder and detrusor ...
1940214 - Changing response of plasmodium falciparum to chloroquine in west bengal during 1980-1988.
24988304 - Changes in use of lipid-lowering medications among black and white dual enrollees with ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2008-09-17
Journal Detail:
Title:  Archives of dermatological research     Volume:  301     ISSN:  1432-069X     ISO Abbreviation:  Arch. Dermatol. Res.     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-24     Completed Date:  2009-02-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8000462     Medline TA:  Arch Dermatol Res     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  65-70     Citation Subset:  IM    
Department of Dermatology, Richard and Adeline Fleischaker Chair in Dermatology Research, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK 73104, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / administration & dosage,  adverse effects*,  chemistry
Autoantibodies / blood,  immunology
Autoantigens / immunology
Biomedical Research*
Bronchial Provocation Tests
Calcium Channel Blockers / administration & dosage,  adverse effects*,  chemistry
Health Planning Guidelines
Hypertension / blood,  complications*,  drug therapy
Lichenoid Eruptions
Lupus Erythematosus, Cutaneous / blood,  chemically induced*,  diagnosis,  physiopathology,  prevention & control
Middle Aged
Photosensitivity Disorders
RNA, Small Cytoplasmic / immunology
Ribonucleoproteins / immunology
Sodium Chloride Symporter Inhibitors / administration & dosage,  adverse effects*,  chemistry
Withholding Treatment
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Autoantibodies; 0/Autoantigens; 0/Calcium Channel Blockers; 0/RNA, Small Cytoplasmic; 0/Ribonucleoproteins; 0/Sodium Chloride Symporter Inhibitors; 0/TROVE2 protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Topical calcineurin inhibitors in cutaneous lupus erythematosus.
Next Document:  The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic ab...